Epigeneron believes that collaboration and strategic partnerships are fundamental to improving business outcomes, and benefit not only us but also our partners. Epigeneron actively pursues such partnering opportunities in every industries such as pharmaceuticals, diagnostics and others based on our two platform technologies, locus-specific ChIP and ORNi-PCR.
See below for more information.
The locus-specific ChIP technologies enable us to explore and identify novel drug targets specifically involved in gene regulation that have not before been discovered by exiting techniques.
Epigeneron is actively pursuing business collaborations with pharmaceutical, diagnostics, clinical testing lab and breeding/synthetic biology companies to contribute to those partners in creating new business value by providing our novel technical solutions utilizing ORNi-PCR.